Neoadjuvant therapy for pancreatic cancer: an ongoing debate.
作者信息
Russo Suzanne, Saif M Wasif
机构信息
Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Tufts University School of Medicine, 800 Washington Street, Suite 7099, 7-S, Boston, MA 02111, USA.
出版信息
Therap Adv Gastroenterol. 2016 Jul;9(4):429-36. doi: 10.1177/1756283X16646524. Epub 2016 May 10.
Abstract
摘要
相似文献
1
Neoadjuvant therapy for pancreatic cancer: an ongoing debate.
Therap Adv Gastroenterol. 2016 Jul;9(4):429-36. doi: 10.1177/1756283X16646524. Epub 2016 May 10.
2
Neoadjuvant therapy for non-metastatic pancreatic ductal adenocarcinoma.
Semin Oncol. 2015 Feb;42(1):86-97. doi: 10.1053/j.seminoncol.2014.12.008. Epub 2014 Dec 9.
3
Neoadjuvant Therapy is Essential for Resectable Pancreatic Cancer.
Curr Med Chem. 2019;26(40):7196-7211. doi: 10.2174/0929867325666180413101722.
4
A neoadjuvant strategy for the management of nonmetastatic pancreatic cancer.
Cancer J. 2012 Nov-Dec;18(6):602-8. doi: 10.1097/PPO.0b013e318279aade.
5
Adjuvant and neoadjuvant therapies in resectable pancreatic cancer: a systematic review of randomized controlled trials.
Med Oncol. 2016 Mar;33(3):28. doi: 10.1007/s12032-016-0742-z. Epub 2016 Feb 17.
6
[Efficacy of neoadjuvant chemotherapy for resectable pancreatic carcinoma].
Gan To Kagaku Ryoho. 2013 Nov;40(12):1632-6.
7
Neoadjuvant therapy in pancreatic cancer: review article.
JOP. 2015 Mar 20;16(2):110-4. doi: 10.6092/1590-8577/2940.
8
[Developments and controversies in neoadjuvant therapy for resectable pancreatic cancer].
Zhonghua Wai Ke Za Zhi. 2020 Jul 1;58(7):486-489. doi: 10.3760/cma.j.cn112139-20200422-00318.
9
Conversion Surgery for Pancreatic Cancer-The Impact of Neoadjuvant Treatment.
Front Oncol. 2020 Jan 14;9:1501. doi: 10.3389/fonc.2019.01501. eCollection 2019.
10
Long-term outcome following neoadjuvant therapy for resectable and borderline resectable pancreatic cancer compared to upfront surgery: a meta-analysis of comparative studies by intention-to-treat analysis.
Surg Today. 2019 Apr;49(4):295-299. doi: 10.1007/s00595-019-01786-w. Epub 2019 Mar 15.
引用本文的文献
1
Four-Tier Pathologic Tumor Regression Grading System Predicts the Clinical Outcome in Patients Who Undergo Surgical Resection for Locally Advanced Pancreatic Cancer after Neoadjuvant Chemotherapy.
Gut Liver. 2022 Jan 15;16(1):129-137. doi: 10.5009/gnl20312.
2
Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma.
Front Oncol. 2020 Sep 16;10:1461. doi: 10.3389/fonc.2020.01461. eCollection 2020.
3
Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX.
Gut Liver. 2021 May 15;15(3):466-475. doi: 10.5009/gnl20070.
4
Completion of adjuvant therapy in patients with resected pancreatic cancer.
HPB (Oxford). 2020 Feb;22(2):241-248. doi: 10.1016/j.hpb.2019.07.008. Epub 2019 Sep 25.
5
Recent advances in radiation therapy of pancreatic cancer.
F1000Res. 2018 Dec 13;7. doi: 10.12688/f1000research.16272.1. eCollection 2018.
6
High compliance with guideline recommendations but low completion rates of adjuvant chemotherapy in resected pancreatic cancer: A cohort study.
Ann Med Surg (Lond). 2018 Jun 27;32:32-37. doi: 10.1016/j.amsu.2018.06.004. eCollection 2018 Aug.
本文引用的文献
1
Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor-vessel relationships.
J Radiat Oncol. 2013 Dec;2(4):413-425. doi: 10.1007/s13566-013-0115-6. Epub 2013 Sep 22.
2
Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
Acta Oncol. 2015 Jul;54(7):979-85. doi: 10.3109/0284186X.2015.1004367. Epub 2015 Mar 3.
3
The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience.
Ann Surg Oncol. 2015 Jul;22(7):2352-8. doi: 10.1245/s10434-014-4274-5. Epub 2015 Jan 7.
4
Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.
Cancer. 2015 Apr 1;121(7):1128-37. doi: 10.1002/cncr.29161. Epub 2014 Dec 23.
5
Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial.
Strahlenther Onkol. 2015 Jan;191(1):7-16. doi: 10.1007/s00066-014-0737-7. Epub 2014 Sep 25.
6
Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749).
BMC Cancer. 2014 Jun 7;14:411. doi: 10.1186/1471-2407-14-411.
7
Trajectory of care and use of multimodality therapy in older patients with pancreatic adenocarcinoma.
Surgery. 2014 Aug;156(2):280-9. doi: 10.1016/j.surg.2014.03.001. Epub 2014 Mar 14.
8
Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity.
Cancer Immunol Res. 2013 Sep;1(3):179-189. doi: 10.1158/2326-6066.CIR-13-0001. Epub 2013 Jul 17.
9
A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma.
Clin Cancer Res. 2013 Nov 15;19(22):6286-95. doi: 10.1158/1078-0432.CCR-13-1320. Epub 2013 Aug 27.
10
Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma.
Ann Surg Oncol. 2013 Nov;20(12):3787-93. doi: 10.1245/s10434-013-3161-9. Epub 2013 Aug 1.
Zotero 插件